Hiroki Masuda Selected Research

Interleukin-6 (Interleukin 6)

9/2022	Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment.
1/2018	Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder.
7/2017	Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: Their possible role on blood-brain barrier disruption.
6/2017	Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroki Masuda Research Topics

Disease

9	Neuromyelitis Optica (Devic's Disease) 09/2022 - 01/2013
9	Multiple Sclerosis 12/2021 - 07/2015
3	Nervous System Diseases (Neurological Disorders) 11/2020 - 06/2017
2	Seizures (Absence Seizure) 09/2022 - 05/2014
2	Neoplasms (Cancer) 08/2020 - 01/2020
2	Inflammation (Inflammations) 01/2018 - 01/2017
2	Infections 09/2003 - 01/2002
2	Human Influenza (Influenza) 09/2003 - 01/2002
2	Parkinson Disease (Parkinson's Disease) 09/2003 - 01/2002
1	Neuralgia (Stump Neuralgia) 09/2022
1	Disease Progression 04/2022
1	Optic Neuritis (Retrobulbar Neuritis) 04/2022
1	Stomach Neoplasms (Stomach Cancer) 01/2022
1	Tissue Adhesions 10/2021
1	Cryptococcal Meningitis 08/2021
1	Myelitis 11/2020
1	Neuroinflammatory Diseases 11/2020
1	Atrophy 08/2019
1	Progressive Multifocal Leukoencephalopathy 05/2018
1	Pain (Aches) 01/2018
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2018
1	Fatigue 01/2018
1	Lymphopenia (Lymphocytopenia) 01/2018
1	Relapsing-Remitting Multiple Sclerosis 07/2017
1	Pure Autonomic Failure 12/2014
1	Epilepsia Partialis Continua 05/2014
1	Hashimoto's encephalitis 05/2014
1	Myoclonus (Nocturnal Myoclonus) 05/2014
1	Brain Diseases (Brain Disorder) 05/2014
1	Sclerosis 01/2013

Drug/Important Bio-Agent (IBA)

5	AntibodiesIBA 11/2020 - 01/2013
4	Interleukin-6 (Interleukin 6)IBA 09/2022 - 06/2017
4	Fingolimod Hydrochloride (FTY720)FDA Link 08/2021 - 09/2015
4	Pharmaceutical PreparationsIBA 08/2019 - 01/2002
3	Myelin-Oligodendrocyte GlycoproteinIBA 04/2022 - 01/2020
3	Immunoglobulin G (IgG)IBA 04/2022 - 01/2020
2	Monoclonal AntibodiesIBA 09/2022 - 01/2020
2	Rotaxanes (Rotaxane)IBA 08/2020 - 01/2020
2	CyclodextrinsIBA 08/2020 - 01/2020
2	CD40 Ligand (CD40L)IBA 01/2018 - 01/2017
2	AlbuminsIBA 01/2018 - 07/2017
2	Amantadine (Aman)FDA LinkGeneric 09/2003 - 01/2002
1	satralizumabIBA 09/2022
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 09/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2022
1	Alemtuzumab (Campath)FDA Link 12/2021
1	Neuroprotective AgentsIBA 12/2021
1	HydrogelsIBA 10/2021
1	CollagenIBA 10/2021
1	polyrotaxaneIBA 10/2021
1	AntigensIBA 08/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	Cysteine (L-Cysteine)FDA Link 01/2020
1	Trastuzumab (Herceptin)FDA Link 01/2020
1	maleimideIBA 01/2020
1	Natalizumab (Tysabri)FDA Link 05/2018
1	Interferon-betaIBA 01/2018
1	CytokinesIBA 07/2017
1	Matrix Metalloproteinases (MMPs)IBA 07/2017
1	InterleukinsIBA 06/2017
1	Aquaporin 4IBA 01/2016
1	Dihydrotachysterol (AT 10)IBA 08/2015
1	AutoantibodiesIBA 07/2015
1	SynucleinsIBA 12/2014
1	erucylphosphocholineIBA 05/2014
1	SteroidsIBA 05/2014
1	Zanamivir (Relenza)FDA Link 09/2003
1	Oseltamivir (Tamiflu)FDA Link 09/2003
1	Antiviral Agents (Antivirals)IBA 09/2003

Therapy/Procedure

2	Therapeutics 12/2021 - 09/2003
2	Duration of Therapy 08/2019 - 05/2018
1	Drug Therapy (Chemotherapy) 01/2020